Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Y. Jenkins · SciRah

Researcher profile · Semantic Scholar

Y. Jenkins

Share profile

Y. Jenkins — researcher profile on SciRah

h-index: 15
Works: 28
Citations: 1,146

Most-cited papers

HIV-1 infection requires a functional integrase NLS.
Michèle Bouyac-Bertoia, Jeffrey D. Dvorin, R. A. Fouchier, Y. Jenkins +4 more
2001Molecules and Cells239 citations Open access
Semantic Scholar
Characterization of HIV-1 Vpr Nuclear Import: Analysis of Signals and Pathways
Y. Jenkins, M. McEntee, K. Weis, W. Greene
1998Journal of Cell Biology217 citations Open access
Semantic Scholar
Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth.
Y. Jenkins, V. Markovtsov, W. Lang, Poonam Sharma +13 more
2005Molecular Biology of the Cell185 citations Open access
Semantic Scholar
Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen
John R. McLaughlin, V. Markovtsov, Hui Li, Steve T. Wong +30 more
2009Journal of Cancer Research and Clinical Oncology67 citations Open access
Semantic Scholar
Biochemical Analyses of the Interactions between Human Immunodeficiency Virus Type 1 Vpr and p6Gag
Y. Jenkins, O. Pornillos, R. Rich, D. Myszka +2 more
2001Journal of Virology67 citations Open access
Semantic Scholar
AMPK Activation through Mitochondrial Regulation Results in Increased Substrate Oxidation and Improved Metabolic Parameters in Models of Diabetes
Y. Jenkins, Tianduo Sun, V. Markovtsov, M. Foretz +35 more
2013PLoS ONE58 citations Open access
Semantic Scholar
Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial
Funda Meric Bernstam, N. Tannir, O. Iliopoulos, Richard J. Lee +16 more
2022Clinical Cancer Research54 citations Open access
Semantic Scholar
CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
F. Meric-Bernstam, Richard J. Lee, B. Carthon, O. Iliopoulos +16 more
2019Journal of Clinical Oncology49 citations
Semantic Scholar
Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.
Kristen A. Baltgalvis, Kathy White, Wei Li, Mark D. Claypool +25 more
2014American Journal of Physiology. Heart and Circulatory Physiology41 citations Open access
Semantic Scholar
Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours
A. Naing, T. Bauer, K. Papadopoulos, O. Rahma +16 more
2019Annals of Oncology37 citations Open access
Semantic Scholar
The AMPK activator R419 improves exercise capacity and skeletal muscle insulin sensitivity in obese mice
K. Marcinko, Adam L. Bujak, J. Lally, R. Ford +8 more
2015Molecular Metabolism36 citations Open access
Semantic Scholar
Nuclear Export of Human Immunodeficiency Virus Type 1 Vpr Is Not Required for Virion Packaging
Y. Jenkins, P. V. Sanchez, B. E. Meyer, M. Malim
2001Journal of Virology24 citations Open access
Semantic Scholar
Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).
N. Tannir, Alice C. Fan, Richard J. Lee, B. Carthon +16 more
201820 citations
Semantic Scholar
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors
M. Yarchoan, J. Powderly, Bruno R Bastos, T. Karasic +16 more
2024Cancer Research Communications16 citations Open access
Semantic Scholar
Global metabolite profiling of mice with high-fat diet-induced obesity chronically treated with AMPK activators R118 or metformin reveals tissue-selective alterations in metabolic pathways
Y. Jenkins, Tianduo Sun, Yingwu Li, V. Markovtsov +8 more
2014BMC Research Notes16 citations Open access
Semantic Scholar
A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
S. Ulahannan, J. Powderly, M. Johnson, J. Krauss +13 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
Optimization of Pharmacokinetic and In Vitro Safety Profile of a Series of Pyridine Diamide Indirect AMPK Activators.
S. J. Shaw, Dane A. Goff, Luke A. Boralsky, Rajinder Singh +8 more
2023Journal of Medicinal Chemistry7 citations Open access
Semantic Scholar
A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).
F. Skoulidis, J. Neal, W. Akerley, P. Paik +9 more
20206 citations
Semantic Scholar
Structure activity relationships leading to the identification of the indirect activator of AMPK, R419.
S. Shaw, D. Goff, D. C. Carroll, Rajinder Singh +8 more
2022Bioorganic & Medicinal Chemistry2 citations Open access
Semantic Scholar
AMPK activation by a novel small molecule of mitochondrial regulation enhances fatty acid oxidation, ketogenesis and branched chain amino acid catabolism in vivo
Y. Hitoshi, Y. Jenkins, V. Markovtsov, Tianduo Sun +21 more
20131 citations
Semantic Scholar
758 Biomarkers associated with blockade of prostaglandin E2 signaling by TPST-1495: a novel, dual-antagonist of E-prostanoid receptors 2 and 4
Nathan Standifer, Y. Jenkins, Sam H. Whiting, Thomas Dubensky
2023Regular and Young Investigator Award Abstracts0 citations Open access
Semantic Scholar
1471 Pharmacodynamic and predictive biomarkers associated with response in cancer patients treated with TPST-1120: a first-in-class, small molecule antagonist of peroxisome-proliferator activated receptor-alpha
N. Standifer, Y. Jenkins, S. Whiting, Thomas Dubensky
2022Late-Breaking Abstracts0 citations Open access
Semantic Scholar
Abstract 3021: Development of small molecule direct AMPK activators for the treatment of cancer
Y. Hitoshi, Y. Jenkins, Yingwu Li, Elmer Sampang +10 more
20160 citations
Semantic Scholar
Friday morning – Abstracts 130-225 WRM 130 Survey of Analytical Techniques Useful for Thin Film Material Evaluation in High Technology Applications
Sambaiah Thota, R. Singh, Xiang Xu, Sarkiz D. Issakani +16 more
20130 citations
Semantic Scholar
Procédés de détection d'inhibiteurs de la dégradation de l'apobec3g favorisée par le vif et du vih
Y. Jenkins, Guo-Ping Su
20080 citations
Semantic Scholar
Modulateurs de la proliferation cellulaire
Y. Hitoshi, Y. Jenkins, V. Markovtsov
20030 citations
Semantic Scholar
Sak: modulation of cell proliferation for the treatment of cancer.
S. Demo, Y. Hitoshi, Y. Jenkins
20020 citations
Semantic Scholar
Sak: modulation of cell proliferation to cancer treatment
S. Demo, Y. Hitoshi, Y. Jenkins
20020 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Y. Hitoshi×14
Invite
Y. Hitoshi — researcher profile on SciRah
V. Markovtsov×9
Invite
V. Markovtsov — researcher profile on SciRah
D. Payan×9
Invite
D. Payan — researcher profile on SciRah
Tianduo Sun×7
Invite
Tianduo Sun — researcher profile on SciRah

×6

Invite

Rajinder Singh — researcher profile on SciRah

Invite

Yingwu Li — researcher profile on SciRah

Invite

D. Goff — researcher profile on SciRah

Invite

S. Shaw — researcher profile on SciRah

Invite

S. Whiting — researcher profile on SciRah

Invite

Gerald Uy — researcher profile on SciRah

Sarkiz D. Issakani×5

Invite

Sarkiz D. Issakani — researcher profile on SciRah

Invite

T. Gururaja — researcher profile on SciRah